



July 21, 2026

Dear Healthcare Professional,

Re: Availability of Hypurin® Porcine Insulin Cartridges through the Special Access Program (SAP)

This notice is to inform health care professionals that Wockhardt UK will support continued access to Hypurin® Porcine Insulin cartridges through Health Canada's Special Access Program (SAP).

Practitioners seeking access to Hypurin® may submit a patient-specific request (Form A) to the SAP. Requests must describe the patient's clinical circumstances and provide clinical rationale in ruling out marketed alternatives. All requests are considered on a case-by-case basis. Please be advised that the submission of a request does not guarantee that authorization for access will be granted.

As a reminder, drugs accessed through the SAP do not undergo a benefit-risk assessment that is typical and required of marketed drug products. Drugs authorized via the SAP are exempt from the *Food and Drugs Act* and *Food and Drug Regulations*. Health Canada recommends that practitioners prescribing Hypurin® should factor the non-authorized status of the drug into their benefit-risk assessments for individual patients.

Should a practitioner wish to access a product, a request can be submitted by fax to the SAP. The forms necessary for submitting a request can be found at the following website <http://www.healthcanada.gc.ca/sap>.

Access to Hypurin through the SAP is expected to be available beginning July 27, 2026.

For additional information or clarification, please contact the SAP at: sapd-pasm@hc-sc.gc.ca

Regards/Meilleures Salutations,

The Special Access Program

www.healthcanada.gc.ca/sap

www.santecanada.gc.ca/pas